Bioject Could Fold In June Without Additional Financing
This article was originally published in The Gray Sheet
Executive Summary
Needle-free drug-delivery systems manufacturer Bioject announced April 7 that it may not be able to continue operations past May 31, despite its best efforts to stay afloat
You may also be interested in...
People In Brief
Diagnostics and diabetes at Roche: Jürgen Schwiezer will take the helm of Roche's diagnostics business in January, the firm announces Oct. 2. He will succeed Severin Schwan, who will become CEO of the Swiss drug and diagnostic company in March (1"The Gray Sheet" July 23, 2007, p. 10). Schwiezer is Roche Diagnostic's president for Europe, Middle East and Africa, the unit's largest market region. Also on Oct. 2, Roche announced that Burkhard G. Piper, who heads the diabetes care division, will report directly to the company CEO beginning in January, rather than reporting to Schwiezer. Roche says it is not creating a separate diabetes business unit to join its pharmaceutical and diagnostic units, but the direct CEO report signals its intention to be more aggressive in the diabetes space, where it holds the number one worldwide position in blood glucose monitors (Accu-Chek) and number two in insulin infusion. Meanwhile, Roche is set to lose its top spot in the worldwide clinical laboratory diagnostics market with Siemens' imminent acquisition of Dade Behring (2"The Gray Sheet" July 30, 2007, p. 4)
People In Brief
Diagnostics and diabetes at Roche: Jürgen Schwiezer will take the helm of Roche's diagnostics business in January, the firm announces Oct. 2. He will succeed Severin Schwan, who will become CEO of the Swiss drug and diagnostic company in March (1"The Gray Sheet" July 23, 2007, p. 10). Schwiezer is Roche Diagnostic's president for Europe, Middle East and Africa, the unit's largest market region. Also on Oct. 2, Roche announced that Burkhard G. Piper, who heads the diabetes care division, will report directly to the company CEO beginning in January, rather than reporting to Schwiezer. Roche says it is not creating a separate diabetes business unit to join its pharmaceutical and diagnostic units, but the direct CEO report signals its intention to be more aggressive in the diabetes space, where it holds the number one worldwide position in blood glucose monitors (Accu-Chek) and number two in insulin infusion. Meanwhile, Roche is set to lose its top spot in the worldwide clinical laboratory diagnostics market with Siemens' imminent acquisition of Dade Behring (2"The Gray Sheet" July 30, 2007, p. 4)
Serono And RJL Systems Plead Guilty To AIDS Drug And Device Fraud
Serono Labs will plead guilty to criminal charges that it offered kickbacks to doctors and conspired with medical device maker RJL Sciences to market an unapproved diagnostic device in order to increase sales of its drug Serostim, used to treat AIDS wasting